"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 4 | 1 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 0 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 3 | 8 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight. 2023 Mar 22; 8(6).
-
COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. J Med Virol. 2023 01; 95(1):e28134.
-
Immunoglobulin ? chain allotypes and humoral immunity to HSV1 in Parkinson's disease. J Neuroimmunol. 2022 10 15; 371:577948.
-
Superimmunity by pan-sarbecovirus nanobodies. Cell Rep. 2022 06 28; 39(13):111004.
-
Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022 05 27; 13(1):2979.
-
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 05 26; 386(21):2011-2023.
-
SARS-CoV-2 Viral Incidence, Antibody Point Prevalence, Associated Population Characteristics, and Vaccine Attitudes, South Carolina, February 2021. Public Health Rep. 2022 May-Jun; 137(3):457-462.
-
Self-administered, remote assessment of SARS-CoV-2 seroprevalence in health care workers. Am J Med Sci. 2022 Sep; 364(3):281-288.
-
IgG3 constant region GM (? marker) allotypes could influence the neutralizing potency of anti-SARS-CoV-2 monoclonal antibodies. Proc Natl Acad Sci U S A. 2022 02 08; 119(6).
-
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. J Clin Virol. 2022 02; 147:105080.